Phase 2 Macular Degeneration Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are between 55 and 80 years old (inclusive) at the time of signing the consent form.
• People with a body mass index (BMI) between 19 and 34 kg/m² (a standard measure of body weight relative to height).
• People who agree to use reliable contraception for at least 12 months after receiving the study treatment; women must not be pregnant or breastfeeding.
• People whose geographic atrophy (GA) lesion meets specific size and location requirements, as confirmed by a central imaging review at the screening stage.
• People whose eyes are clear enough, dilate adequately, and can remain steady enough to allow good-quality eye images to be taken, as judged by the study investigator.
• People whose treated eye has a specific level of visual acuity on a standardised eye chart, depending on which part of the study they are entering (confirm with trial site for exact thresholds).
• People whose other (non-treated) eye meets a minimum level of vision on a standardised eye chart, and whose non-treated eye has equal or better vision than the treated eye.

Who may not be able to join:

• People who have any eye disease or condition other than geographic atrophy caused by age-related macular degeneration (AMD), including wet AMD, a history of abnormal blood vessel growth in either eye, active eye infections, a history of certain eye surgeries (such as vitrectomy, retinal detachment repair, or corneal transplant) in the treated eye, or a history of uveitis (eye inflammation).
• People whose eye condition prevents clear imaging from being taken.
• People with medical, thinking, or mental health conditions that, in the investigator's opinion, would make it difficult to complete 12 months of follow-up visits or could increase health risks from participating.
• People who were hospitalised within the past year for a reason that, in the investigator's opinion, could affect their ability to complete the study or increases their risk of harm.
• People whose screening test results (such as heart tracings or blood tests) are considered clinically significant by the investigator or medical monitor.
• People who have a medical reason they cannot take steroids (both oral and topical), or a condition that significantly raises the risk of complications from a steroid regimen.
• People with an active or recent cancer diagnosis within the past 5 years, or who have had radiation therapy near the treated eye; certain past skin cancers and treated localised prostate cancer may not be exclusionary (confirm with trial site).
• People who have had eye surgery (including lens replacement) within 3 months before screening.
• People with a history of laser treatment in the central area of the retina (the macula).
• People who have received injections into the eye, such as steroid injections, within 6 months before screening.
• People who have received a COVID-19 vaccine within 90 days before screening, or who plan to receive one within 6 months of receiving the study treatment.
• People who have been actively using systemic (whole-body) immune-suppressing drugs or oral/injected corticosteroids within the past 60 days; topical (applied to skin) steroids are not excluded.
• People who have taken part in another interventional clinical trial for geographic atrophy within the past 12 months.

Important: Always verify eligibility with the trial site directly before applying.